UroMems
UroMems makes an active implantable artificial urinary sphincter urologists implant for stress incontinence, matching urethral pressure to activity automatically.
Founded
2011UroMems makes an active implantable artificial urinary sphincter urologists implant for stress incontinence, matching urethral pressure to activity automatically.
uromems.comCrawled Oct 16, 2026
UroMems aims at revolutionizing the treatment of stress urinary incontinence with smart active implants, using the latest technological advances in the field of embedded systems and micro-technologies.
UroActive is an implant to treat SUI powered by a MyoElectroMechanical System (MEMS). It is placed around the urethral duct and designed for remote control based on patient activity, without manual adjustments.
The page lists UroMems conference presentations at AUA 2025, EAU 2025, and SUFU 2025, including one-year results from the first-in-human SOPHIA study of an artificial urinary sphincter.
The page lists journal publications on UroActive, including a 2026 human assessment, a 2025 cadaver urodynamic comparison with AMS800, and a 2024 RAM2 publication.
“Now, at 1 year, the 1-hour pad test has been done again, as it’s part of the protocol, and she suffered 4 g of incontinence on this test, opposed to 125 g at the beginning,” says Emmanuel Chartier-Kastler, MD, PhD.
UroMems announced that the first female patient implanted with UroActive met the six-month primary endpoint.
Sama brings operational expertise to UroMems as the company prepares pivotal clinical trials for UroActive, an implant to treat stress urinary incontinence.
BOARD OF DIRECTORS Board Members Board Observers
Celia Hart, PhD, represents Supernova Invest and has more than 20 years of experience in the chemical and biotechnology sector. She joined CEA Investissement, now Supernova Invest, in 2005 and is an Investment Director and Partner.
Dan Rose is Chairman of the Board at UroMems and has more than 25 years of experience in the medical device industry. He guides the company as it prepares for pivotal clinical trials and the commercial launch of UroActive.
UroMems focuses on designing, developing, and commercializing active implantable medical devices.
UroMems lists contact details for its France and United States offices, including addresses, phone numbers, and info@uromems.com.
UroMems is developing breakthrough, automated technology to treat stress urinary incontinence (SUI) providing an improved quality of life for women and men.
UroMems says UroActive is under development, with its properties, performance, and safety still under evaluation. It is not available for prescription, delivery, sale, or use by patients or health care professionals.
UroMems secures **$60 million** in funding to advance clinical trials of its smart urology implant, aimed at enhancing treatments for urinary disorders. The implant integrates advanced technology to monitor and manage conditions non-invasively. The funding will support large-scale testing to validate safety and efficacy before potential commercialization.
May 2026 · VentureburnNews article
UroMems secures $60 million from Ajax Health to advance its **UroActive System**, a smart implant for stress urinary incontinence (SUI). The funding supports pivotal clinical trials and prepares for commercial launch. The device automates treatment delivery for patients with SUI, a condition affecting millions.
May 2026 · Pulse 2.0News article
UroMems secures a $60 million investment from the U.S.-based **Ajax Health Fund I** to advance its implantable mechatronics technology for treating **stress urinary incontinence (SUI)**. The company specializes in developing innovative medical devices aimed at improving patient outcomes in urological care. This funding supports further research and commercialization of its proprietary solutions.
May 2026 · PR NewswireNews article
UroMems initiates a pivotal clinical study for its **UroActive™ smart implant**, a mechatronics-based treatment for **male stress urinary incontinence (SUI)**. The company secures **IDE approval from the FDA and French ANSM**, following positive feasibility results from earlier trials in France. The implant targets a condition affecting millions, leveraging proprietary technology to restore urinary control.
Jul 2025 · UroMemsNews article